Basel, Switzerland (PRWEB) June 17, 2014
Genedata, a leading provider of advanced software solutions for drug and life science research, today announced the release of Genedata Screener® 12. This latest version of the industry’s single-platform screening solution provides: new capabilities for data analysis of technologies such as Surface Plasmon Resonance (SPR), Thermal Shift, Combination and Panel Screens; broadens workflow support; and minimizes data analysis time. Genedata Screener 12 features advanced image management functionality and a newly- designed Analyzer module, which optimizes user efficiency and productivity -- from loading data to generating final analysis results. Addressing emerging research requirements, Genedata Screener 12 broadens the portfolio of innovative screening data analyses that can be handled in a single software system.
Platform Enhancements Increase Screening Productivity & Improve Data Analysis Results
Used by leading pharmaceutical companies, CROs, and academic research institutions, Genedata Screener is the infrastructure-shaping solution for all types of screening projects. Supporting high throughput and a broad range of screening technologies, it delivers the industry’s fastest data loading and calculation capabilities. Now, it also completely automates processing, from data import to results. This high degree of automation is especially useful in multi-step data analysis such as dose-response curve and compound combination experiments and in pre-processing for time-series and single-cell data. While ease-of-use enhancements help increase user adoption organization-wide, the new release also has time-saving features that minimize system maintenance and enable analysis workflows for newer technologies and applications. Moreover, version 12 enables the platform to be easily customized to handle specific applications, technologies, and customer requirements.
Highlights of Genedata Screener version 12:
“Genedata Screener has established itself as the software of choice for all plate-based screening technologies,” said Dr. Othmar Pfannes, CEO of Genedata. “As a single-platform solution, it creates cost efficiencies, streamlines and standardizes data analysis, and accommodates new technologies and applications such as biophysical and compound combination experiments. With version 12, we enable researchers to fully leverage the most advanced technologies used in their drug discovery process and we are fully committed to continually advancing this platform to meet their evolving needs.”
Genedata transforms data into intelligence with a portfolio of advanced software solutions, which make research data accessible and understandable and research processes more efficient. These solutions are used worldwide by leading pharmaceutical, industrial, and agricultural biotechnology companies as well as academic research organizations. Genedata innovations enable scientific discovery that fights disease and improves health and quality of life worldwide. Founded in 1997, Genedata is headquartered in Switzerland, and has offices in Germany, Japan, and the US. http://www.genedata.com. Follow Us on LinkedIn
The statements in this press release that relate to future plans, events or performance are forward-looking statements that involve risks and uncertainties, including risks associated with uncertainties related to contract cancellations, developing risks, competitive factors, uncertainties pertaining to customer orders, demand for products and services, development of markets for the Company's products and services. Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof. The Company undertakes no obligation to release publicly the result of any revisions to these forward-looking statements that may be made to reflect events or circumstances after the date hereof or to reflect the occurrence of unanticipated events.
All product and service names mentioned are the trademarks of their respective companies.